Search International and National Patent Collections

1. (WO2004029055) FUSED AZOLE-PYRIMIDINE DERIVATIVES

Pub. No.:    WO/2004/029055    International Application No.:    PCT/EP2003/010377
Publication Date: Apr 8, 2004 International Filing Date: Sep 18, 2003
IPC: C07D 471/14
C07D 487/04
C07D 519/00
Applicants: BAYER PHARMACEUTICALS CORPORATION
SHIMADA, Mitsuyuki
MURATA, Toshiki
FUCHIKAMI, Kinji
TSUJISHITA, Hideki
OMORI, Naoki
KATO, Issei
MIURA, Mami
URBAHNS, Klaus
GANTNER, Florian
BACON, Kevin
Inventors: SHIMADA, Mitsuyuki
MURATA, Toshiki
FUCHIKAMI, Kinji
TSUJISHITA, Hideki
OMORI, Naoki
KATO, Issei
MIURA, Mami
URBAHNS, Klaus
GANTNER, Florian
BACON, Kevin
Title: FUSED AZOLE-PYRIMIDINE DERIVATIVES
Abstract:
The present invention relates to hovel fused azolepyrimidine derivatives, processes for preparing them and pharmaceutical preparations containing them. The fused azolepyrimidine derivatives of the present invention exhibit enhanced potency for phosphotidylinositol-3-kinase (P13K) inhibition, especially for PI3K-Ϝ inhibition and can be used for the prophylaxis and treatment of diseases associated with P13K and particularly with P13K-Ϝ activity. More specifically, the azole derivatives of the present invention are useful for treatment and prophylaxis of diseases as follows: inflammatory and immunoregulatory disorders, such as asthma, atopic dermatitis, rhinitis, allergic diseases, chronic obstructive pulmonary disease (COPD), septic shock, joint diseases, autoixnmune pathologies such as rheumatoid arthritis, and Graves' disease, cancer, myocardial contractility disorders, heart failure, thromboembolism, ischemia, and atherosclerosis. The compounds of the present invention are also useful for pulmonary hypertension, renal failure, cardiac hypertrophy, as well as neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease, diabetes and focal ischemia, since the diseases also relate to P13K activity in a human or animal subject.